{"disease":{"id":"metastatic-breast-cancer-her2-positive","name":"metastatic breast cancer her2 positive"},"drugs":{"marketed":[{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":10,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03617341","title":"Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07132242","title":"SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":84,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}